{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:48:07Z","timestamp":1787028487442,"version":"build-2736575974"},"reference-count":16,"publisher":"American Association for Cancer Research (AACR)","issue":"10","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The role of chronic inflammation and arachidonic acid (AA) metabolism in tumor progression has been well characterized for variety of cancers, with compelling data for colon cancer. Several preclinical and clinical studies primarily focused on inhibiting the cyclooxygenase pathways using NSAIDs and aspirin for colon cancer prevention. However, emerging evidence clearly supports the pro-tumorigenic role of 5-lipoxygenase and its downstream leukotriene pathway within AA metabolism. As discussed in the current issue, targeting the leukotriene pathway by cysteinyl leukotriene receptor antagonist (LTRA) montelukast suppressed formation of aberrant crypt foci (ACF) and cell proliferation in colonic epithelium, suggesting the potential of LTRAs for colon cancer prevention. Although this is a short clinical chemoprevention trial to explore the effects of LTRAs against ACF development, it is a significant and timely study opening avenues to further explore the possibilities of using LTRAs in other inflammation-associated precancerous lesions as well. In this spotlight commentary, we highlight the implications of their data and the opportunities for developing LTRAs as potential candidates for colorectal cancer interception.<\/jats:p>\n                  <jats:p>See related article by Higurashi et al., p. 661<\/jats:p>","DOI":"10.1158\/1940-6207.capr-22-0331","type":"journal-article","created":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T03:22:09Z","timestamp":1664853729000},"page":"637-640","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Targeting the Leukotriene Pathway for Colon Cancer Interception"],"prefix":"10.1158","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1058-6909","authenticated-orcid":false,"given":"Altaf","family":"Mohammed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3608-1714","authenticated-orcid":false,"given":"Robert H.","family":"Shoemaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2022,10,4]]},"reference":[{"key":"2025112418201578900_bib1","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"2025112418201578900_bib2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1158\/1940-6207.CAPR-22-0038","article-title":"Role of prostaglandin E2 in the progression of gastrointestinal cancer","volume":"15","author":"Wilson","year":"2022","journal-title":"Cancer Prev Res"},{"key":"2025112418201578900_bib3","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa061652","article-title":"Celecoxib for the prevention of colorectal adenomatous polyps","volume":"355","author":"Arber","year":"2006","journal-title":"N Engl J Med"},{"key":"2025112418201578900_bib4","doi-asserted-by":"crossref","first-page":"6355","DOI":"10.3748\/wjg.v12.i39.6355","article-title":"Expression of 5-lipoxygenase in human colorectal cancer","volume":"12","author":"Soumaoro","year":"2006","journal-title":"World J Gastroenterol"},{"key":"2025112418201578900_bib5","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1056\/NEJMra071371","article-title":"Leukotrienes","volume":"357","author":"Peters-Golden","year":"2007","journal-title":"N Engl J Med"},{"key":"2025112418201578900_bib6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1254\/jphs.FP0060651","article-title":"Blockade of leukotriene B4 signaling pathway induces apoptosis and suppresses cell proliferation in colon cancer","volume":"103","author":"Ihara","year":"2007","journal-title":"J Pharmacol Sci"},{"key":"2025112418201578900_bib7","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.3389\/fphar.2020.01289","article-title":"Leukotrienes in tumor-associated inflammation","volume":"11","author":"Tian","year":"2020","journal-title":"Front Pharmacol"},{"key":"2025112418201578900_bib8","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/978-1-4419-9194-2_43","article-title":"The leukotriene receptor CysLT1 and 5-lipoxygenase are upregulated in colon cancer","volume":"525","author":"Nielsen","year":"2003","journal-title":"Adv Exp Med Bio"},{"key":"2025112418201578900_bib9","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3390\/ijms23010120","article-title":"Cysteinyl leukotriene pathway and cancer","volume":"23","author":"Tsai","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2025112418201578900_bib10","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1158\/1940-6207.CAPR-22-0049","article-title":"Leukotriene receptor antagonist therapy for the chemoprevention of human rectal aberrant crypt foci: nonrandomized, open-label, controlled trial","volume":"15","author":"Higurashi","year":"2022","journal-title":"Cancer Prev Res"},{"key":"2025112418201578900_bib11","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.3390\/cancers2031705","article-title":"Aberrant crypt Foci: the case for inclusion as a biomarker for colon cancer","volume":"2","author":"Wargovich","year":"2010","journal-title":"Cancers"},{"key":"2025112418201578900_bib12","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0304-3835(87)90157-1","article-title":"Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings","volume":"37","author":"Bird","year":"1987","journal-title":"Cancer Lett"},{"key":"2025112418201578900_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1207\/S15327914NC431_1","article-title":"Most effective colon cancer chemopreventive agents in rats: a systematic review of aberrant crypt foci and tumor data, ranked by potency","volume":"43","author":"Corpet","year":"2002","journal-title":"Nutr Cancer"},{"key":"2025112418201578900_bib14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12885-020-6590-4","article-title":"Rectal aberrant crypt foci (ACF) as a predictor of benign and malignant neoplastic lesions in the large intestine","volume":"20","author":"Kowalczyk","year":"2020","journal-title":"BMC Cancer"},{"key":"2025112418201578900_bib15","doi-asserted-by":"crossref","first-page":"e00047","DOI":"10.14309\/ctg.0000000000000047","article-title":"Rectal aberrant crypt Foci in humans are not surrogate markers for colorectal cancer risk","volume":"10","author":"Quintanilla","year":"2019","journal-title":"Clin Transl Gastroenterol"},{"key":"2025112418201578900_bib16","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.bcp.2013.05.005","article-title":"Cysteinyl leukotriene-receptor-1 antagonists interfere with PGE2 synthesis by inhibiting mPGES-1 activity","volume":"86","author":"Kahnt","year":"2013","journal-title":"Biochem Pharmacol"}],"container-title":["Cancer Prevention Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article-pdf\/15\/10\/637\/3208764\/637.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article-pdf\/15\/10\/637\/3208764\/637.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T23:20:23Z","timestamp":1764026423000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article\/15\/10\/637\/709270\/Targeting-the-Leukotriene-Pathway-for-Colon-Cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,4]]},"references-count":16,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10,4]]},"published-print":{"date-parts":[[2022,10,4]]}},"URL":"https:\/\/doi.org\/10.1158\/1940-6207.capr-22-0331","relation":{},"ISSN":["1940-6207","1940-6215"],"issn-type":[{"value":"1940-6207","type":"print"},{"value":"1940-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,4]]}}}